Resection of Flexor Digitorum Superficialis Tendon for Severe Trigger Fingers
Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Dec 17, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different surgical methods to treat severe trigger finger, a condition that can cause pain and difficulty moving the fingers. Specifically, the study will compare the effectiveness of removing a part of a specific tendon in the finger versus cutting a structure called the A1 pulley, which can also help relieve the symptoms.
To be eligible for this trial, participants need to be adults (18 years or older) who are experiencing limited movement in their finger due to this condition. However, if the finger's stiffness is caused by another illness, or if there are serious health issues that could complicate surgery, those individuals won't be able to participate. If you decide to join the trial, your experience will involve undergoing one of the surgical procedures and attending follow-up appointments to assess how well the treatment is working. This study is currently recruiting participants of all genders aged between 65 and 74 years.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥18 years old) with a flexor tendon tenosynovitis of a finger resulting in a decreased range of motion of the PIP joint (defined with a palm-to-pulp distance ≥0mm and/or flexion contracture ≥15°).
- Exclusion Criteria:
- • Minors (\<18 years old).
- • PIP joint contracture resulting from another illness than stenosing flexor tenosynovitis (for example: rheumatoid arthritis) or caused by a traumatic event.
- • Contraindications to any surgery: presence of a severe coagulation disorder, immunosuppression or decompensated psychiatric illness.
About Centre Hospitalier Universitaire Vaudois
The Centre Hospitalier Universitaire Vaudois (CHUV) is a leading academic medical center located in Lausanne, Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUV plays a pivotal role in translating scientific discoveries into transformative therapies, enhancing patient care across a diverse range of medical disciplines. With a multidisciplinary team of experts and state-of-the-art facilities, CHUV is dedicated to fostering collaboration and delivering high-quality evidence that informs clinical practice and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vd, Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials